Skip to main content
Top
Published in: Osteoporosis International 2/2021

Open Access 01-02-2021 | Care | Original Article

The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study

Authors: E. McCloskey, J. Rathi, S. Heijmans, M. Blagden, B. Cortet, E. Czerwinski, P. Hadji, J. Payer, K. Palmer, R. Stad, J. O’Kelly, S. Papapoulos

Published in: Osteoporosis International | Issue 2/2021

Login to get access

Abstract

Summary

This study in 8 countries across Europe found that about 75% of elderly women seen in primary care who were at high risk of osteoporosis-related fractures were not receiving appropriate medication. Lack of osteoporosis diagnosis appeared to be an important contributing factor.

Introduction

Treatment rates in osteoporosis are documented to be low. We wished to assess the osteoporosis treatment gap in women ≥ 70 years in routine primary care across Europe.

Methods

This cross-sectional observational study in 8 European countries collected data from women 70 years or older visiting their general practitioner. The primary outcome was treatment gap: the proportion who were not receiving any osteoporosis medication among those at increased risk of fragility fracture (using history of fracture, 10-year probability of fracture above country-specific Fracture Risk Assessment Tool [FRAX] thresholds, T-score ≤ − 2.5).

Results

Median 10-year probability of fracture (without bone mineral density [BMD]) for the 3798 enrolled patients was 7.2% (hip) and 16.6% (major osteoporotic). Overall, 2077 women (55%) met one or more definitions for increased risk of fragility fracture: 1200 had a prior fracture, 1814 exceeded the FRAX threshold, and 318 had a T-score ≤ − 2.5 (only 944 received a dual-energy x-ray absorptiometry [DXA] scan). In those at increased fracture risk, the median 10-year probability of hip and major osteoporotic fracture was 11.2% and 22.8%, vs 4.1% and 11.5% in those deemed not at risk. An osteoporosis diagnosis was recorded in 804 patients (21.2%); most (79.7%) of these were at increased fracture risk. The treatment gap was 74.6%, varying from 53% in Ireland to 91% in Germany. Patients with an osteoporosis diagnosis were found to have a lower treatment gap than those without a diagnosis, with an absolute reduction of 63%.

Conclusions

There is a large treatment gap in women aged ≥ 70 years at increased risk of fragility fracture in routine primary care across Europe. The gap appears to be related to a low rate of osteoporosis diagnosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ström O, Borgström F, Kanis JA et al (2011) Osteoporosis: burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155CrossRef Ström O, Borgström F, Kanis JA et al (2011) Osteoporosis: burden, health care provision and opportunities in the EU. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 6:59–155CrossRef
2.
go back to reference Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023–2034CrossRef Kanis JA, Cooper C, Rizzoli R et al (2017) Identification and management of patients at increased risk of osteoporotic fracture: outcomes of an ESCEO expert consensus meeting. Osteoporos Int 28:2023–2034CrossRef
3.
go back to reference Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRef Hernlund E, Svedbom A, Ivergård M et al (2013) Osteoporosis in the European Union: medical management, epidemiology and economic burden. A report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos 8:136CrossRef
4.
go back to reference Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364–376CrossRef Compston JE, McClung MR, Leslie WD (2019) Osteoporosis. Lancet 393:364–376CrossRef
5.
go back to reference Chenot R, Scheidt-Nave C, Gabler S, Kochen MM, Himmel W (2007) German primary care doctors’ awareness of osteoporosis and knowledge of national guidelines. Exp Clin Endocrinol Diabetes 115:584–589CrossRef Chenot R, Scheidt-Nave C, Gabler S, Kochen MM, Himmel W (2007) German primary care doctors’ awareness of osteoporosis and knowledge of national guidelines. Exp Clin Endocrinol Diabetes 115:584–589CrossRef
6.
go back to reference Lespessailles E, Cotté F-E, Roux C, Fardellone P, Mercier F, Gaudin A-F (2009) Prevalence and features of osteoporosis in the French general population: the Instant study. Joint Bone Spine 76:394e400CrossRef Lespessailles E, Cotté F-E, Roux C, Fardellone P, Mercier F, Gaudin A-F (2009) Prevalence and features of osteoporosis in the French general population: the Instant study. Joint Bone Spine 76:394e400CrossRef
7.
go back to reference Sahota O, Worley A, Hosking J (2000) An audit of current clinical practice in the management of osteoporosis in Nottingham. Journal of Public Health Medicine 22:466–472CrossRef Sahota O, Worley A, Hosking J (2000) An audit of current clinical practice in the management of osteoporosis in Nottingham. Journal of Public Health Medicine 22:466–472CrossRef
8.
go back to reference Judge A, Javaid MK, Leal J, et al (2016) Chapter 7: Primary care and hospital care costs for hip fracture patients. In: Models of care for the delivery of secondary fracture prevention after hip fracture: a health service cost, clinical outcomes and cost-effectiveness study within a region of England. NIHR Journals Library, Southampton, UK. Health Services and Delivery Research;4.28. https://www.ncbi.nlm.nih.gov/books/NBK385602/. Accessed Sept 20, 2019 Judge A, Javaid MK, Leal J, et al (2016) Chapter 7: Primary care and hospital care costs for hip fracture patients. In: Models of care for the delivery of secondary fracture prevention after hip fracture: a health service cost, clinical outcomes and cost-effectiveness study within a region of England. NIHR Journals Library, Southampton, UK. Health Services and Delivery Research;4.28. https://​www.​ncbi.​nlm.​nih.​gov/​books/​NBK385602/​. Accessed Sept 20, 2019
10.
go back to reference Marsh D, Åkesson K, Beaton DE (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065CrossRef Marsh D, Åkesson K, Beaton DE (2011) Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int 22:2051–2065CrossRef
11.
go back to reference Kanis JA, Svedbom A, Harvey N et al (2014) The osteoporosis treatment gap. J Bone Miner Res 29:1926–1928CrossRef Kanis JA, Svedbom A, Harvey N et al (2014) The osteoporosis treatment gap. J Bone Miner Res 29:1926–1928CrossRef
12.
go back to reference McCloskey E, Rathi J, Heijmans S et al (2019) Osteoporosis (OP) diagnosis and treatment of women aged ≥70 years in primary care: results from a large European cross-sectional study. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Paris, France, April 4–7, (poster P997) McCloskey E, Rathi J, Heijmans S et al (2019) Osteoporosis (OP) diagnosis and treatment of women aged ≥70 years in primary care: results from a large European cross-sectional study. World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Paris, France, April 4–7, (poster P997)
13.
go back to reference Díez-Pérez A, Hooven FH, Adachi JD et al (2011) Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49:493–498CrossRef Díez-Pérez A, Hooven FH, Adachi JD et al (2011) Regional differences in treatment for osteoporosis. The Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 49:493–498CrossRef
15.
go back to reference Briot K, Roux C, Thomas T, Blain H et al (2018) 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine 85:519–530CrossRef Briot K, Roux C, Thomas T, Blain H et al (2018) 2018 update of French recommendations on the management of postmenopausal osteoporosis. Joint Bone Spine 85:519–530CrossRef
16.
go back to reference Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 30:3–44CrossRef Kanis JA, Cooper C, Rizzoli R et al (2019) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis Int 30:3–44CrossRef
17.
go back to reference Shepstone L, Lenaghan E, Cooper C et al (2018) for SCOOP Study Team. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391:741–747CrossRef Shepstone L, Lenaghan E, Cooper C et al (2018) for SCOOP Study Team. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet 391:741–747CrossRef
18.
go back to reference Dennison EM, Compston JE, Flahive J et al (2012) Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50:1288–1293CrossRef Dennison EM, Compston JE, Flahive J et al (2012) Effect of co-morbidities on fracture risk: findings from the Global Longitudinal Study of Osteoporosis in Women (GLOW). Bone 50:1288–1293CrossRef
19.
go back to reference Raherison C, Girodet P-O (2009) Epidemiology of COPD. Eur Respir Rev 18:213–221CrossRef Raherison C, Girodet P-O (2009) Epidemiology of COPD. Eur Respir Rev 18:213–221CrossRef
20.
go back to reference Lorentzon M, Nilsson AG, Johansson H, Kanis JA, Mellström D, Sundh D (2019) Extensive undertreatment of osteoporosis in older Swedish women. Osteoporosis International 30:1297–1305CrossRef Lorentzon M, Nilsson AG, Johansson H, Kanis JA, Mellström D, Sundh D (2019) Extensive undertreatment of osteoporosis in older Swedish women. Osteoporosis International 30:1297–1305CrossRef
21.
go back to reference Hiligsmann M, Cornelissen D, Vrijens B et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 30:2155–2165CrossRef Hiligsmann M, Cornelissen D, Vrijens B et al (2019) Determinants, consequences and potential solutions to poor adherence to anti-osteoporosis treatment: results of an expert group meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) and the International Osteoporosis Foundation (IOF). Osteoporos Int 30:2155–2165CrossRef
22.
go back to reference Cipriani C, Pepe J, Minisola S, Lewiecki EM (2018) Adverse effects of media reports on the treatment of osteoporosis. J Endocrinol Invest 41:1359–1364CrossRef Cipriani C, Pepe J, Minisola S, Lewiecki EM (2018) Adverse effects of media reports on the treatment of osteoporosis. J Endocrinol Invest 41:1359–1364CrossRef
23.
go back to reference Wuab CH, Tuc ST, Chang YF et al (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone 111:92–110CrossRef Wuab CH, Tuc ST, Chang YF et al (2018) Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone 111:92–110CrossRef
24.
go back to reference Rubin KH, Rothmann MJ, Holmberg T et al (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 29:567–578CrossRef Rubin KH, Rothmann MJ, Holmberg T et al (2018) Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 29:567–578CrossRef
25.
go back to reference Merlijn T, Swart KM, van Schoor NM et al (2019) The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res 34:1993–2000CrossRef Merlijn T, Swart KM, van Schoor NM et al (2019) The effect of a screening and treatment program for the prevention of fractures in older women: a randomized pragmatic trial. J Bone Miner Res 34:1993–2000CrossRef
26.
go back to reference Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM (2020) Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 31:251–257CrossRef Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM (2020) Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 31:251–257CrossRef
27.
go back to reference Chotiyarnwong P, Harvey NC, Johansson H et al (2019) Temporal changes in access to FRAX(R) in Thailand between 2010 and 2018. Arch Osteoporos 14:66CrossRef Chotiyarnwong P, Harvey NC, Johansson H et al (2019) Temporal changes in access to FRAX(R) in Thailand between 2010 and 2018. Arch Osteoporos 14:66CrossRef
Metadata
Title
The osteoporosis treatment gap in patients at risk of fracture in European primary care: a multi-country cross-sectional observational study
Authors
E. McCloskey
J. Rathi
S. Heijmans
M. Blagden
B. Cortet
E. Czerwinski
P. Hadji
J. Payer
K. Palmer
R. Stad
J. O’Kelly
S. Papapoulos
Publication date
01-02-2021
Publisher
Springer London
Published in
Osteoporosis International / Issue 2/2021
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI
https://doi.org/10.1007/s00198-020-05557-z

Other articles of this Issue 2/2021

Osteoporosis International 2/2021 Go to the issue